早期类风湿关节炎介入治疗安全性的系统综述与网络Meta分析
该系统综述与网络Meta分析纳入20项双盲随机对照试验、共9202例早期RA患者,评估不同治疗策略的安全性。Meta分析显示严重不良事件合并发生率为69.8/1000人年,严重感染为18.9/1000人年。网络Meta分析表明生物制剂单药治疗的严重不良事件率高于甲氨蝶呤单药及生物制剂联合治疗,但各策略间严重感染和非严重不良事件率无显著差异。
要点
- 生物制剂单药严重不良事件率高于MTX单药(RR 1.39)及MTX联合激素(RR 3.22)。
- 生物制剂单药不良事件率高于生物制剂联合治疗(RR 1.26)。
- 各策略间严重感染和非严重不良事件率无显著差异,激素方案未显更危险。
核心结论
- 早期RA不同治疗策略风险特征不同,但总体差异较小;与已确立RA研究不同,激素方案未显示更高危害。
研究设计与样本
- 系统检索MEDLINE、EMBASE和PubMed至2020年9月,纳入20项双盲随机对照试验,共9202例完全未治或MTX未治的早期RA患者,排除长期扩展研究、事后和汇总分析及无对照臂试验。
主要发现
- Meta分析合并每1000人年发生率:严重不良事件69.8(95%CI 64.9, 74.8),严重感染18.9(95%CI 16.2, 21.6),非严重不良事件1048.2(95%CI 1027.5, 1068.9)。
- 网络Meta分析显示生物制剂单药严重不良事件率高于MTX单药,率比1.39(95%CI 1.12, 1.73)。
- 生物制剂单药严重不良事件率高于MTX联合激素治疗,率比3.22(95%CI 1.47, 7.07)。
- 生物制剂单药不良事件率高于生物制剂联合治疗,率比1.26(95%CI 1.02, 1.54)。
- 网络Meta分析未发现各策略间严重感染和非严重不良事件率有显著差异。
临床怎么用
- 早期RA选择生物制剂单药治疗时需关注严重不良事件风险,联合治疗可能降低风险。
- 激素方案在早期RA中未显示更高危害,但需结合个体情况评估。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the safety of treatment strategies in patients with early RA. METHODS: Systematic searches of MEDLINE, EMBASE and PubMed were conducted up to September 2020. Double-blind randomized controlled trials (RCTs) of licensed treatments conducted on completely naïve or MTX-naïve RA patients were included. Long-term extension studies, post-hoc and pooled analyses and RCTs with no comparator arm were excluded. Serious adverse events, serious infections and non-serious adverse events were extracted from all RCTs, and event rates in intervention and comparator arms were compared using meta-analysis and network meta-analysis (NMA). RESULTS: From an initial search of 3423 studies, 20 were included, involving 9202 patients. From the meta-analysis, the pooled incidence rates per 1000 patient-years for serious adverse events were 69.8 (95% CI: 64.9, 74.8), serious infections 18.9 (95% CI: 16.2, 21.6) and non-serious adverse events 1048.2 (95% CI: 1027.5, 1068.9). NMA showed that serious adverse event rates were higher with biologic monotherapy than with MTX monotherapy, rate ratio 1.39 (95% CI: 1.12, 1.73). Biologic monotherapy rates were higher than those for MTX and steroid therapy, rate ratio 3.22 (95% CI: 1.47, 7.07). Biologic monotherapy had a higher adverse event rate than biologic combination therapy, rate ratio 1.26 (95% CI: 1.02, 1.54). NMA showed no significant difference between strategies with respect to serious infections and non-serious adverse events rates. CONCLUSION: The study revealed the different risk profiles for various early RA treatment strategies. Observed differences were overall small, and in contrast to the findings of established RA studies, steroid-based regimens did not emerge as more harmful.
引用
- Adas MA, Allen VB, Yates M, et al. A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis. Rheumatology (Oxford). 2021. PMID: 34003970. doi:10.1093/rheumatology/keab429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。